Clinical Outcomes, Costs, and Healthcare Resource Utilization in Patients with Metastatic Merkel Cell Carcinoma Treated with Immune Checkpoint Inhibitors vs Chemotherapy

PURPOSE: Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer with poor prognosis. This study compared patient characteristics, comorbidities, adverse events (AEs), treatment persistence, healthcare resource utilization (HRU) and costs in patients with metastatic MCC (mMCC) treated with imm...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Clinicoecon Outcomes Res
Главные авторы: Zheng, Ying, Yu, Ting, Mackey, Rachel H, Gayle, Julie A, Wassel, Christina L, Phatak, Hemant, Kim, Ruth
Формат: Artigo
Язык:Inglês
Опубликовано: Dove 2021
Предметы:
Original Research
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC8001053/
https://ncbi.nlm.nih.gov/pubmed/33790597
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CEOR.S290768
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы